How pharma can help the post-COVID recovery of European cancer care

How pharma can help the post-COVID recovery of European cancer care

The publication, which has been supported by Accord Healthcare, also provides a series of recommendations for how the pharmaceutical industry can continue to support cancer care for the next 12 months and looks at what physicians want, and need, from the industry.

It’s clear that the acute phase of the pandemic had a huge impact on cancer care across Europe. Healthcare services were repurposed to combat COVID-19, surgical procedures postponed, screening programmes paused, and patients avoided healthcare facilities.

In the UK, urgent consultant diagnosis cancer referrals plummeted by 60% in April 2020, not only swelling subsequent waiting lists but possibly resulting in many patients’ diseases being at a more serious stage when they are eventually seen.

Logo